TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2024 Ended Jun 30, 2024 | Aug 20, 2024 | During market hours | $15.80M | $-0.71 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 1, 2024 | During market hours | $14.70M | $-0.18 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 10, 2023 | Before market open | $14.80M | $-0.15 | – |
Press releases
Announcements Trinity Biotech filed with the SEC
(Incorporated and registered in Ireland with registered number 183476)
EX-99.2 to Form 6-K
(Incorporated and registered in Ireland with registered number 183476)
EX-99.3 to Form 6-K
Paul Murphy Dave Gentry, CEO
EX-99.1 to Form 6-K
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
EX-99.1 to Form 6-K
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
EX-99.1 to Form 6-K
Trinity Biotech Announces Successful Clinical Results For Its
EX-99.1 to Form 6-K
Trinity Biotech Senior Executives to Attend ATTD 2026 to
EX-99.1 to Form 6-K
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring
EX-99.2 to Form 6-K
Biotech Announces Further Major Technical
EX-99.1 to Form 6-K
Trinity Biotech Provides Business and Trading Update
EX-99.2 to Form 6-K
Trinity Biotech Secures $25 Million Financing Commitment to
EX-99.2 to Form 6-K
Trinity Biotech Receives Non-Compliance Notice Regarding
EX-99.1 to Form 6-K
Trinity Biotech Receives Non-Compliance Notice Regarding
EX-99.1 to Form 6-K
Trinity Biotech Glucose Monitoring Innovation Achieves Unique
EX-99.1 to Form 6-K
Trinity Biotech Secures Regulatory Approval for Commencement
EX-99.2 to Form 6-K
SECOND AMENDMENT TO SIXTH AMENDED AND RESTATED CREDIT AGREEMENT AND GUARANTY
EX-99.1 to Form 6-K
Press Release dated December 23, 2025
EX-99.1 to Form 6-K
Trinity Biotech Expands Global Rollout of High-Capacity Column
EX-99.1 to Form 6-K
DRAFT – Confidential Until Released
EX-99.1 to Form 6-K
Trinity Biotech Announces Collaboration to Advance
EX-99.1 to Form 6-K
A PUBLIC COMPANY LIMITED BY SHARES
EX-99.1 to Form 6-K
First Amendment to Sixth Amended and Restated Credit Agreement and Guaranty
EX-99.2 to Form 6-K
This report has been prepared in accordance with the Companies Act 2014
EX-99.1 to Form 6-K
(Incorporated and registered in Ireland with registered number 183476)
EX-99.2 to Form 6-K